AstraZeneca Posts $16.21 Billion in Q3 Revenue, Reaffirms 2026 Outlook
Photo: TokenPost
AstraZeneca posted third-quarter revenue of $16.21 billion and reaffirmed its 2026 outlook Friday, as sales climbed 7% year over year and Core EPS reached $2.79. Revenue came to $16.21 billion. Full-year guidance calls for total revenue to grow by a mid- to high-single-digit percentage, while Core EPS is expected to increase by a low double-digit percentage at constant exchange rates. The earlier earnings preview listed a rounded $16 billion consensus estimate for quarterly revenue. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
